Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Free heme refers to the iron-containing porphyrin molecule (iron protoporphyrin IX) that is not bound within hemoproteins. In its unbound state, free heme is highly reactive and toxic due to its ability to catalyze the formation of reactive oxygen species (ROS) and activate inflammatory pathways. Elevated levels are observed in hemolytic diseases, transfusion reactions, and tissue injury, contributing to organ dysfunction. Detoxification mechanisms include binding by plasma proteins, cellular export, and enzymatic degradation.
Many therapeutic strategies aim to neutralize or remove free heme, rather than directly interact with it in a traditional drug-target sense. These include enhancing heme scavenging by haptoglobin/hemopexin, promoting heme degradation via heme oxygenase, or inhibiting the inflammatory signaling pathways activated by heme.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Free Heme.